ClinicalTrials.gg
RecruitingNCT07432009ORTOPODCZUpdated Jul 9, 2026

Orthopedic Procedures and Postoperative Delirium in Older Adults in the Czech Republic

An observational study in Frailty, Cognitive Impairment and Older Adults, sponsored by Tomas Bata Hospital, Czech Republic. Recruiting at 7 sites in Czechia. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Tomas Bata Hospital, Czech Republic · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
65 Years and older
Sex
All
01

Study summary

This multicenter, prospective, non-interventional observational study (ORTOPODCZ) investigates the association between preoperative cognitive impairment and postoperative delirium (POD) in older adults undergoing elective total hip arthroplasty in the Czech Republic. Postoperative delirium is a frequent and serious neurocognitive complication in senior surgical patients and is associated with increased morbidity, mortality, prolonged hospitalization, and impaired functional and cognitive outcomes. Despite international recommendations, routine preoperative cognitive screening remains insufficiently implemented.

The study evaluates the predictive value of the ALBA test, a brief cognitive screening tool, performed during the pre-anesthetic assessment. Postoperative delirium will be assessed using the validated CAM-ICU instrument for up to 72 hours after surgery. Secondary objectives include assessing the relationship between POD and frailty, polypharmacy, comorbidities, type of anesthesia, intraoperative hemodynamics, blood loss, vasoactive support, and postoperative complications.

Approximately 300-400 participants aged ≥65 years will be enrolled across seven centers. No additional procedures, biological sampling, or deviations from standard clinical care are required. Data will be collected in REDCap and analyzed according to a predefined statistical analysis plan. The study aims to provide robust evidence supporting the integration of cognitive screening into routine preoperative evaluation and to describe feasibility and implementation requirements for the ALBA test in clinical practice.

Read the detailed description

Postoperative delirium (POD) is one of the most common perioperative neurocognitive disorders in older adults undergoing elective orthopedic procedures, particularly total hip arthroplasty. It is associated with adverse outcomes including increased morbidity, mortality, prolonged hospitalization, and long-term cognitive decline. Although international guidelines recommend routine preoperative cognitive assessment, its implementation in clinical practice remains limited.

This study builds on findings from a pilot project demonstrating the feasibility and potential predictive value of the ALBA test, a brief cognitive screening tool. The primary objective is to evaluate the association between ALBA test results (normal vs. pathological) and the occurrence of POD within 72 hours after surgery, diagnosed using the CAM-ICU instrument. Secondary objectives include assessing the relationship between POD and frailty (Clinical Frailty Scale), polypharmacy, comorbidities, preoperative anemia, type of anesthesia, intraoperative hemodynamic instability, blood loss, vasoactive medication use, reoperations, and postoperative complications.

The study is designed as a multicenter, prospective, non-interventional observational study conducted in seven hospitals in the Czech Republic. All participants will receive standard perioperative care without additional procedures or biological sampling. Cognitive screening (ALBA) will be performed during the pre-anesthetic assessment, and delirium monitoring (CAM-ICU) will be conducted at predefined intervals for up to 72 hours postoperatively. Data will be collected in REDCap and analyzed according to a predefined statistical analysis plan. The study also includes exploratory evaluation of the feasibility, acceptability, and implementation requirements of integrating the ALBA test into routine preoperative workflows.

02

Conditions studied

  • Frailty
  • Cognitive Impairment
  • Older Adults
  • Hip Arthroplasty
  • Postoperative Delirium

Keywords

  • ALBA test
  • CAM-ICU
  • Cognitive Screening
  • Geriatric Patients
  • Perioperative Neurocognitive Disorders
  • Polypharmacy
  • Clinical Frailty Scale
  • Total Hip Replacement
  • Observational Study
  • Prospective Cohort
03

In context

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 400 is above the median of 225 across 495 observational studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

Tomas Bata Hospital, Czech Republic is the lead sponsor of 11 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Prospective cohort of patients aged 65 years and older undergoing elective total hip arthroplasty in seven hospitals in the Czech Republic. All participants receive standard perioperative care. No interventions are assigned as part of the study; only observational data are collected.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 65 years
  • Elective total hip arthroplasty in general or regional anesthesia
  • I-III
  • Ability to understand and cooperate during testing; no severe sensory impairment (compensatory aids allowed)
  • Expected postoperative hospitalization in ICU, PACU, or standard ward

Exclusion criteria

Exclusion Criteria:

  • Glasgow Coma Scale ≤ 14
  • Limited legal capacity
  • Active psychiatric disorder (e.g., psychotic disorder, bipolar disorder)
  • Active oncological disease
  • Chronic use of strong opioids
  • Premedication with anxiolytics or antipsychotics during preanesthetic evaluation
  • Acute reoperation within 3 months of primary surgery
  • Refusal to participate or withdrawal of consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort of older adults undergoing elective total hip arthroplasty

    Prospective cohort of patients aged 65 years and older undergoing elective total hip arthroplasty in standard clinical care. All participants receive routine perioperative management. No interventions are assigned as part of the study.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative delirium (POD)

    POD will be assessed using the CAM-ICU tool. Delirium is considered present if at least one CAM-ICU assessment is positive within the first 72 hours after surgery. The outcome will be expressed as the percentage of patients with POD.

    Time frame: 0-72 hours after surgery

Secondary outcomes

  1. Frailty score measured using the Clinical Frailty Scale (CFS)

    Frailty will be assessed preoperatively using the Clinical Frailty Scale (CFS), which ranges from 1 to 9. Frailty is defined as CFS ≥ 4. The outcome will be expressed as the frailty score on the CFS scale. Frailty will be assessed preoperatively using the Clinical Frailty Scale (CFS), which ranges from 1 to 9. Frailty is defined as CFS ≥ 4. The outcome will be expressed as the frailty score on the CFS scale.Frailty will be assessed preoperatively using the Clinical Frailty Scale (CFS), which ranges from 1 to 9. Frailty is defined as CFS ≥ 4. The outcome will be expressed as the frailty score on the CFS scale.

    Time frame: Preoperative assessment

  2. Number of comorbidities present preoperatively

    Comorbidities will be recorded preoperatively, including cerebrovascular disease, cardiovascular disease, diabetes mellitus, chronic kidney disease, and others. The outcome will be expressed as the total number of comorbidities per patient.

    Time frame: Preoperative assessment

  3. Presence of polypharmacy (>5 regular medications)

    Polypharmacy will be assessed preoperatively and defined as the regular use of more than five medications. The outcome will be expressed as the percentage of patients meeting the definition of polypharmacy.

    Time frame: Preoperative medication list

  4. Presence of preoperative anemia

    Anemia will be assessed preoperatively according to local laboratory reference ranges. The outcome will be expressed as the percentage of patients who meet the definition of anemia. Anemia will be assessed preoperatively according to local laboratory reference ranges. The outcome will be expressed as the percentage of patients who meet the definition of anemia.

    Time frame: Preoperative assessment

  5. Type of anesthesia used (general vs. regional)

    The type of anesthesia will be recorded as general anesthesia or regional anesthesia. The outcome will be expressed as the percentage of patients receiving each anesthesia type.

    Time frame: 0-72 hours after surgery

  6. Duration of urinary catheterization (hours)

    The duration of urinary catheterization (PMK) will be recorded daily from surgery until catheter removal. The outcome will be expressed as the total number of hours of urinary catheterization.

    Time frame: 0-72 hours after surgery

  7. Presence of reoperation within 72 hours after surgery

    Reoperation will be assessed as a binary variable (yes/no) within 72 hours after surgery. The outcome will be expressed as the percentage of patients who undergo reoperation.

    Time frame: 0-72 hours after surgery

  8. Intraoperative blood loss (milliliters)

    ntraoperative blood loss will be measured in milliliters as recorded by the surgical team. The outcome will be expressed as the total volume of blood loss during surgery.

    Time frame: Intraoperative period

  9. Use of vasoactive drugs during surgery

    The use of vasoactive drugs (e.g., noradrenaline, phenylephrine, ephedrine) will be assessed as a binary variable (yes/no) during the intraoperative period. The outcome will be expressed as the percentage of patients who receive vasoactive drugs.

    Time frame: Intraoperative period

07

Study locations

1 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this is a multicenter observational study conducted under strict GDPR requirements. The study does not include a data-sharing framework or governance structure that would allow external access to pseudonymized datasets. Data will be used exclusively for the purposes defined in the study protocol and handled according to institutional and national data protection regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2029, 44 months after the start.

Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 44 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 25, 2026
StartActual
Apr 24, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Mar 31, 2030
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07432009
Lead sponsor
Tomas Bata Hospital, Czech Republic
Collaborators
Czech Clinical Research Infrastructure Network
Responsible party
Klára Nekvindová (Principal Investigator, Department of Anesthesiology, Resuscitation and Intensive Car, Tomas Bata Hospital, Czech Republic) — Principal investigator
First posted
Feb 25, 2026
Start date
Apr 24, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Jul 9, 2026

Study contacts

Klára Nekvindová, M.D, Ph.D.
Contact
nekvindova.klara@gmail.com
+420577 551 111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion